BioVentures Investors, a Wellesley, MA-based venture capital firm focused on medtech, held the first close of its fourth fund, at $29.3m.
According to a regulatory form filed with the SEC, BioVentures Investors IV Limited Partnership has a final target of $100m.
Led by Peter Feinsteinm Walter Gilbert, Marc Goldberg, Jeffrey Barnes, and Stephen Liu, BioVentures Investors backs medtech companies investing a total of $3-$10m in each operation.
Upon closing of Fund IV, the firm will have have more than $233m under management in four funds. Portfolio companies include Angiolink, BioValve, CardioSolutions, Claros Diagnostics, Cylene Pharmaceuticals, Enanta Pharmaceuticals, HealthCare IT, Hydra Biosciences, HydroCision, MoMelan Technologies, Phase Forward, Pintex Pharmaceuticals (Acquired by Vernalis), Rachiotek, Rcadia Medical Imaging, Spirus Medical, Verax Biomedical, Verax Biomedical, Vital Sensors, and Zalicus.
FinSMEs
05/08/2016